- Q4 2023 Altimmune Inc Earnings Call TranscriptMar 27, 2024$8.7 (-0.26%)Earnings
- Altimmune Inc Conference Call TranscriptDec 01, 2023
- Q3 2023 Altimmune Inc Earnings Call TranscriptNov 07, 2023$2.55 (-4.36%)Earnings
- Altimmune Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Altimmune Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 Altimmune Inc Earnings Call TranscriptAug 10, 2023$3.15 (+6.77%)Earnings
- Altimmune Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Altimmune Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q1 2023 Altimmune Inc Earnings Call TranscriptMay 11, 2023$5.24 (+8.94%)Earnings
- Altimmune Inc Conference Call TranscriptMar 21, 2023
- Q4 2022 Altimmune Inc Earnings Call TranscriptFeb 28, 2023$11.94Earnings
- Altimmune Inc Topline Results of Pemvidutide in Subjects with NAFLD Call TranscriptDec 20, 2022
- Altimmune Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Q3 2022 Altimmune Inc Earnings Call TranscriptNov 10, 2022$10Earnings
- Altimmune Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference TranscriptOct 18, 2022
- Altimmune Inc Conference Call TranscriptSep 14, 2022
- Q2 2022 Altimmune Inc Earnings Call TranscriptAug 11, 2022$13.3 (+3.14%)Earnings
- Altimmune Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Altimmune Inc Earnings Call TranscriptMay 12, 2022$3.99 (+0.63%)Earnings
- Q4 2021 Altimmune Inc Earnings Call TranscriptMar 15, 2022$6.03 (-9.66%)Earnings
- Q3 2021 Altimmune Inc Earnings Call TranscriptNov 10, 2021$11.06 (+2.50%)Earnings
- Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Altimmune Inc to Host Key Opinion Leader Call on Pemvidutide Phase 1 Clinical Trial Results - Conference Call TranscriptSep 30, 2021
- Altimmune Inc to Discuss the 12-Week Data from Phase 1 Clinical Trial of ALT-801 - Conference Call TranscriptSep 28, 2021
- Q2 2021 Altimmune Inc Earnings Call TranscriptAug 11, 2021$10.63 (+4.22%)Earnings
- Altimmune Inc Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers Conference Call TranscriptJun 16, 2021
- Q1 2021 Altimmune Inc Earnings Call TranscriptMay 17, 2021$13Earnings
- Altimmune Inc to Present AdCOVIDâ„¢ intranasal COVID-19 at the World Vaccine Congress TranscriptMay 04, 2021
- Q4 2020 Altimmune Inc Earnings Call TranscriptFeb 25, 2021$18.13 (-8.72%)Earnings
- Q3 2020 Altimmune Inc Earnings Call TranscriptNov 10, 2020$9.54 (-12.24%)Earnings
- Altimmune Inc Annual Shareholders Meeting TranscriptSep 24, 2020
- Q2 2020 Altimmune Inc Earnings Call TranscriptAug 12, 2020Earnings
- Altimmune Inc Acceptance of IND for Covid-19 Therapeutic Testing - Call TranscriptJun 01, 2020
- Q1 2020 Altimmune Inc Earnings Call TranscriptMay 14, 2020Earnings
- Q4 2019 Altimmune Inc Earnings Call TranscriptMar 27, 2020Earnings
- Q2 2019 Altimmune Inc Earnings Call TranscriptAug 14, 2019Earnings
Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
My name is Patrick Trucchio, and I am a Senior Biotech Analyst at H.C. Wainwright. It's my pleasure to introduce our next presenters, Vipin Garg, CEO; and Scott Harris, Chief Medical Officer of Altimmune, a clinical stage biopharmaceutical company focusing on developing treatments for obesity and liver disease. So I think maybe just to start, if we could talk about Altimmune's synthetic peptide technology platform, how did this come to be in its current form and what makes it differentiated from others in the market?
Yes. Thanks, Patrick. Thank you for having us. So as you know, we are developing two different therapeutic candidates, both peptide-based, based on synthetic peptide platform technology, and we have made specific modifications to this peptide -- to these peptides to accomplish a specific goal. For instance, to increase half-life of the peptide molecule. So our first candidate is ALT-801, or Pemvidutide. It is a GLP-1 glucagon dual agonist
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)